News | May 14, 2022
CCMB develops India’s first mRNA vaccine technology
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes – detecting four infections simultaneously
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
This is the first major brand refresh of CanSinoBIO since its inception in 2009
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
Subscribe To Our Newsletter & Stay Updated
